Literature DB >> 6582247

Reduced pulsatile growth hormone secretion in children after therapy for acute lymphoblastic leukemia.

J Blatt, B B Bercu, J C Gillin, W B Mendelson, D G Poplack.   

Abstract

Basal growth hormone levels were measured every 20 minutes over 24 hours in eight long-term survivors of acute lymphoblastic leukemia and in 13 age- and pubertal stage-matched normal children. Among the patients, the median total basal growth hormone output (AUC) was 43 units, compared with 341 units in the normal control group (P less than 0.001). In the patients, mean pulse amplitude (6.9 ng/ml) and frequency (4.6) over 24 hours also were reduced, compared with the control values (32 ng/ml and 8.5, P less than 0.001 and P less than 0.05, respectively). In addition, normal children secreted more GH at night (median AUC 280) than during the day (113, P less than 0.001). However, this diurnal pattern was absent in three of the patients studied. These data suggest that perturbations of spontaneous pulsatile GH secretion are common after standard therapy for ALL and may be a sensitive means of detecting therapy-related neuroendocrine damage. Blunting of spontaneous pulsatile GH secretion may contribute to the abnormalities in growth seen in children with ALL.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6582247     DOI: 10.1016/s0022-3476(84)80989-0

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  16 in total

Review 1.  Endocrine sequelae of cancer therapy in childhood.

Authors:  F B Diamond; B B Bercu
Journal:  J Endocrinol Invest       Date:  2001-10       Impact factor: 4.256

Review 2.  Pediatric brain tumor treatment: growth consequences and their management.

Authors:  Sogol Mostoufi-Moab; Adda Grimberg
Journal:  Pediatr Endocrinol Rev       Date:  2010-09

Review 3.  Endocrine changes after pediatric traumatic brain injury.

Authors:  Susan R Rose; Bethany A Auble
Journal:  Pituitary       Date:  2012-09       Impact factor: 4.107

4.  Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622.

Authors:  William B Slayton; Kirk R Schultz; John A Kairalla; Meenakshi Devidas; Xinlei Mi; Michael A Pulsipher; Bill H Chang; Charles Mullighan; Ilaria Iacobucci; Lewis B Silverman; Michael J Borowitz; Andrew J Carroll; Nyla A Heerema; Julie M Gastier-Foster; Brent L Wood; Sherri L Mizrahy; Thomas Merchant; Valerie I Brown; Lance Sieger; Marilyn J Siegel; Elizabeth A Raetz; Naomi J Winick; Mignon L Loh; William L Carroll; Stephen P Hunger
Journal:  J Clin Oncol       Date:  2018-05-29       Impact factor: 44.544

Review 5.  Hypopituitarism as a consequence of brain tumours and radiotherapy.

Authors:  Ken H Darzy; Stephen M Shalet
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

6.  Current issues in the management of children with acute lymphocytic leukaemia.

Authors:  D Pinkel
Journal:  Postgrad Med J       Date:  1985-02       Impact factor: 2.401

7.  Lack of mitogenic effects of growth hormone on human leukemic lymphoblasts.

Authors:  J Blatt; S Wenger; S Stitely; P A Lee
Journal:  Eur J Pediatr       Date:  1987-05       Impact factor: 3.183

Review 8.  Hypopituitarism following radiotherapy.

Authors:  Ken H Darzy; Stephen M Shalet
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

9.  Growth and growth hormone in children during and after therapy for acute lymphoblastic leukaemia.

Authors:  M Caruso-Nicoletti; M Mancuso; G Spadaro; S P Dibenedetto; A DiCataldo; G Schiliró
Journal:  Eur J Pediatr       Date:  1993-09       Impact factor: 3.183

10.  Relationship between urinary and serum growth hormone and pubertal status.

Authors:  E C Crowne; W H Wallace; S M Shalet; G M Addison; D A Price
Journal:  Arch Dis Child       Date:  1992-01       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.